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Abstract    
Mutations in the STE20-related kinase adaptor α (STRADA) gene have been reported to cause 
an autosomal recessive neurodevelopmental disorder characterized by infantile-onset epilepsy, 
developmental delay, and cranio-facial dysmorphisms. To date, there have been 17 reported 
individuals diagnosed with STRADA mutations, 16 of which are from a single Old Order 
Mennonite cohort and share a deletion of exons 9-13. The remaining individual is of 
consanguineous Indian descent and has a homozygous single base pair duplication. We report a 
novel STRADA gene deletion of exons 7-9 in two sisters from non-consanguineous parents, as 
well as an improvement in seizure control in one sibling following treatment with sirolimus, an 
m-Tor inhibitor of potential benefit to patients with this genetic mutation. 
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 Introduction 
 
The STRADA gene, located on 17q23.3, contains 13 exons and encodes STE20-related kinase 
adaptor protein. It is translated into the pseudokinase protein STE20-related kinase adapter 
protein α (STRADα/STRADA), which is an upstream inhibitor of the mammalian target of 
rapamycin complex 1 (mTORC1). [1] Mutations in STRADA have been associated with a rare 
clinical neurodevelopmental syndrome,first described in a cohort of 16 Old Order Mennonite 
patients, all of whom shared a terminal deletion in the STRADA gene and whose disorder was 
termed Polyhydramnios, Megalencephaly, and Symptomatic Epilepsy Syndrome (PMSE). [2] An 
additional patient of consanguineous parents with a similar phenotype was subsequently found 
to have a single base pair duplication in the same gene, causing a translational frameshift and 
premature termination. [3] Mutations in STRADA have been shown to cause activation of the 
mTOR pathway, potentially indicating a therapeutic target for mTOR inhibiting medications. [4] 
We describe two sisters of non-consanguineous parents with a novel pathogenic STRADA 
mutation and their response to treatment with sirolimus, an mTOR inhibitor.  
 
Clinical report 
 
Patient A, the older sibling, is a 16 year old girl of Caucasian descent born at 34+4 weeks 
gestation following a pregnancy complicated by polyhydramnios. She was noted to have mild 
epicanthal folds, prominent nasolabial folds, full lips, and macrocephaly (Figure 1A). As an 
infant she was hypotonic and had poor weight gain.   
 
[Insert Figure 1] 
 
Global developmental delays were present throughout. She did not sit independently until age 
4, and she began to stand at age 9. She has remained non-verbal and non-ambulatory to date. 
She developed stereotyped and repetitive behaviors, and was diagnosed with autism spectrum 
disorder.  Obstructive sleep apnea was present as an infant, and at age three she was 
diagnosed with nephrocalcinosis and nephrolithiasis, requiring nephrolithotomy. 
Hypothyroidism was later diagnosed at age 10. 
 
Radiographically she was found to have hypoplastic distal phalanges in all toes, mild hypoplasia 
of the distal first phalange on one hand, and mild pectus carinatum. Magnetic resonance 
imaging (MRI) at nine months of age showed moderate-to-severe diffuse white matter volume 
loss, and the most recent MRI at age 15 showed additionally mild cerebellar volume loss, focal 
encephalomalacia of the left middle temporal gyrus, and severe foramen magnum stenosis due 
to due to the presence of os odontoideum and ligamentous laxity (Figure 2A and 2B). Muscle 
biopsy identified a deficiency in complex 1, leading to an initial diagnosis of possible 
mitochondrial cytopathy. 
 
[Insert figure 2] 
  
At 4 months of age, the patient developed tonic motor seizures of unknown onset with 
duration of 30 to 60 seconds, and was initially treated with phenobarbital with good response. 
At 6 months of age, the patient developed infantile spasms, which were confirmed on 
electroencephalography demonstrating an ictal pattern of high amplitude sharp wave 
discharges on a hypsarrhythmic background. Infantile spasms initially remitted following 
treatment with adrenocorticotropic hormone (ACTH), but would recur around one year of age. 
Throughout her childhood, she continued to have refractory focal and bilateral clonic seizures, 
with multiple seizures daily and periodic status epilepticus. Her epilepsy would prove refractory 
to multiple anticonvulsants. 
Patient B, the younger sister, is currently 13 years old. She was born at 38 weeks gestation 
following a pregnancy also complicated by mild polyhydramnios. She had facial dysmorphism 
similar to her older affected sibling (figure 1B). Neonatally she had feeding dysfunction and 
aspiration requiring gastrostomy tube placement.  
A post-natal renal ultrasound was normal, but a follow-up study at 7 months of age revealed 
nephrocalcinosis, which would remain largely stable until her most recent renal ultrasound at 
age 13. She did not develop hydronephrosis or frank nephrolithiasis.  Her first brain MRI at 4 
months of age showed periventricular leukomalacia and subsequent imaging has shown a 
stable moderate degree of cerebral white matter volume loss and a few small foci of 
nonspecific gliosis in the frontal and parietal subcortical white matter (Figure 2C and 2D).  Sleep 
study at age 5 showed severe central sleep apnea. 
In regards to her epilepsy, she first had a left focal tonic seizure at 4 months of age, and EEG at 
that time demonstrated left temporal-occipital sharps. She was treated with phenobarbital. By 
8 months of age she developed infantile spasms associated with a hypsarrthymic EEG. These 
responded to ACTH therapy, and all seizures remitted until age 5 while she was maintained on 
lamotrigine. At that time she had onset of focal motor seizures with impaired consciousness, 
and her EEG evolved to show severe diffuse slowing and multifocal sharps, most prominent in 
the bitemporal areas. Her seizures would prove refractory to multiple anticonvulsants, and she 
experienced multiple bouts of status epilepticus, until age 10. At that time she was started on 
valproic acid, and she had a period of seizure remission for several years before they ultimately 
returned and would subsequently prove medically refractory to date.  
 
Materials and Methods 
Whole exome sequencing was performed through GeneDx.  Patient A and parental serum 
samples were obtained and tested using XomeDxPlus, which combines whole exome 
sequencing with mitochondrial genome sequencing and deletion testing. The patient’s sample 
was run on the Agilent Clinical Research Exome Kit. Exonic regions and flanking intronic splice 
junctions were sequenced simultaneously by massively parallel (NextGen) sequencing on an 
Illumina HiSeq 2000 instrument. 100 base pair reads were bidirectionally sequenced, 
assembled, and aligned to the GRCh37/UCSC hg19 reference sequence. Sequences were 
analyzed for variants using Xome Analyzer analysis tool. Capillary sequencing was used to 
confirm pathogenic variants.       
 
Results 
Exome sequencing of patient A identified a novel homozygous 4kb deletion in the STRADA gene 
of exons 7-9 at chr17:61,780,815-61,784,837, respectively. GeneDx clinical test XomeDxPlus 
was utilized for the patient’s genetic testing. This deletion is at the 3 prime end of the STRADA 
gene in the protein kinase domain. Functional studies have not been done to verify RNA 
transcript or protein function. Only loss of function mutations have been reported associated 
with STRADA, and it is likely this deletion also causes loss of function. [3] Parental samples from 
the exome trio showed bilineal inheritance of a heterozygous deletion of exons 7-9 of the 
STRADA gene. Polymerase chain reaction (PCR) analysis through GeneDx was done for patient B 
which revealed an identical homozygous deletion. 
 
Intervention 
Sirolimus binds to FKBP-12, an intracellular protein, to form an immunosuppressive complex which 
inhibits the regulatory kinase, mTOR.[5] Based on previous studies suggesting benefit in regards to 
epilepsy following treatment with an m-Tor inhibitor, both sisters were treated with sirolimus 
oral solution at 0.5 mg/m2/dose once daily. [6] Doses were adjusted on a weekly basis initially 
to achieve a target trough level of 5–15 ng/mL. Of note, Patient B was on phenobarbital, which 
is a known CYP3A4 inducer. After one year of sirolimus therapy, the family reported that 
Patient A’s seizure frequency has decreased significantly. Where previously she was having 
multiple daily seizures, after treatment her seizure frequency decreased to where she would 
have days without seizures, and could go as long as 5 days without a seizure. This decrease was 
quantified in a seizure log maintained by her parents, which unfortunately was not started until 
3 months after beginning therapy (Figure 3). Her parents also reported subjective improvement 
in her behavior, attention, and a decrease in somnolence.  
[Insert figure 3] 
Patient B, however, continued to have many seizures per day. Her sirolimus trough levels 
remained low despite increasing her dose, likely due to co-commitant phenobarbital therapy. 
Attempts were made to wean phenobarbital in the hope of increasing her sirolumus levels, 
which was not tolerated due to an increase in seizure burden. She did show some mild, 
subjective improvements in alertness, but had no other obvious benefits to therapy. Similar to 
that reported in the Mennonite children, no obvious effects on expressive language, gross 
motor function, or adaptive learning were reported in either sibling. [1] Sirolimus was tolerated 
well, the only side effect being hypertriglyceridemia, which was treated with finofibrate. 
 
Discussion   
This novel STRADA exon 7-9 deletion, in addition to the previously described case of a 5-year-
old boy with a single base duplication, demonstrates that pathogenic changes in this gene occur 
outside of the Old Order Mennonite community. Despite homozygosity for an exon 7-9 deletion 
in the STRADA gene, there is no reported or clinically suspected consanguinity in this case. 
While we cannot discount the possibility of the parents being distantly related beyond the 
known family history, homozygosity for a rare gene mutation in a suspected rare disorder can 
also be explained by potential mutational hotspots or coincidentally occurring mutations.  
Either mechanism implies that STRADA mutations may not be limited to restricted populations 
and may be an under-recognized in children with infantile epileptic encephalopathies. While 
several of these syndromes are clinically distinct, they may be difficult to differentiate 
phenotypically. Accurate diagnosis is important as prognosis, recurrence risk, and potential for 
treatment may vary. STRADA-related disorders may be one of a relatively small number of 
these disorders for which treatment of the underlying defect has shown promise, although 
further study is needed to establish the efficacy of m-Tor inhibitors in these disorders.  
Given that our patients’ phenotype is severe and similar to that described in the Mennonite 
population, it is possible that they have a similar biochemical phenotype that would also 
respond to sirolimus therapy, although our patients differed from that previously reported in 
several ways.  First, their mutation differed from that described in the Mennonite population, 
which may cause different functional effects on the STRADA protein and the mTORC1 pathway.  
Secondly, our subjects were significantly older at the time of treatment, so it is possible earlier 
treatment would have resulted in a more robust response. Ultimately, patient A seemed to 
show a sustained improvement in seizure control, while no clear effect was seen in patient B.   
STRADA mutations are associated with a severe early-onset childhood epilepsy phenotype. 
While these children have several features that may differentiate their disorder  from other 
severe childhood epilepsies, such as nephrocalcinosis and megaloencephaly, the phenotype 
may otherwise overlap significantly with other infantile epileptic encephalopathies.  Our cases 
demonstrate that this disorder occurs outside of a sequestered population, and suggests these 
disorders have a potential specific therapy. We propose that early identification of STRADA-
associated disorders allows more effective surveillance, anticipatory guidance, and potential 
treatment for affected children.  We also propose that STRADA mutation analysis be added to 
the increasingly comprehensive next-generation sequencing panels now available for infantile 
and childhood epilepsies.   
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 Figure 1A and 1B: Both sisters (patient A being the elder) affected by the same STRADA 
mutation showed similar dysmorphic features 
 
Figure 2: Axial FLAIR MRI images from Patient A showing focal encephalomalacia in the left 
temporal lobe (2A). Patient A (2B) and Patient B (2C and 2D) demonstrated a decrease in white 
matter volume with punctate T2 white matter hyperintensities 
 
Figure 3: Seizure log demonstrating decrease in seizure burden for patient A following sirolimus 
treatment  
 
 
 
 
 
 
 
 
